# The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer

> **NCT07704645** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Resectable Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection
- **DRUG:** Adebrelimab Injection combined with HRS-7058 Capsule

## Key facts

- **NCT ID:** NCT07704645
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-06
- **Final completion:** 2029-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07704645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07704645, "The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07704645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*